Heterocyclic Compounds

Matches 1,001 - 1,050 out of 2,444	< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 >

Document	Document Title
JP2023540081A	Quinoline CGAS antagonist compounds The present disclosure provides compounds that are cGAS antagonists, methods for preparing the compounds, pharmaceutical compositions containing the compounds, and their use in medical therapy.
JP2023130435A	MODIFIED LIGAND-DEPENDENT ION CHANNEL, AND METHOD FOR USING THE SAME To provide a material and a method for adjusting ligand-dependent ion channel (LGIC) activity which can be used for adjusting the excitability of cells in a mammal.Provided is a modified LGIC including at least one LGIC subunit having a ...
JP2023130361A	PREPARATION OF SEIMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITOR AND APPLICATION THEREOF To provide a preparation of semicarbazide-sensitive amine oxidase inhibitor and the application thereof.In particular, there are disclosed compounds as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt...
JP2023538619A	1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis Disclosed is formula (I): or a salt or prodrug thereof, where Q1,Q2,G,R1and R5is defined here. Also disclosed are methods of using such compounds as inhibitors of TLR9 and pharmaceutical compositions containing such compounds. These comp...
JP2023538524A	Compositions that modulate splicing Small molecule splicing regulator compounds that modulate splicing of mRNAs, such as pre-mRNAs encoded by genes, and methods of using small molecule splicing regulator compounds to modulate splicing and treat diseases and conditions are ...
JP2023126574A	POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS To provide compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists.In the formula (I), ring A is aryl or heteroaryl; ring B is aryl or heteroaryl; and X is C(R4...
JP2023536589A	Piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for treating MTAP-deficient and/or MTA-accumulating cancers Compounds are provided according to formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined in It is contemplated that the compounds of the ...
JP2023108032A	BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS To provide benzenesulfonamide compounds and their use as therapeutic agents.This invention is directed to benzenesulfonamide compounds (which are compounds as stereoisomers, enantiomers or tautomers thereof or mixtures thereof), or pharm...
JP7313354B2	Amide-Substituted Indole Compounds Useful as TLR Inhibitors N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions...
JP7312749B2	Methods and compositions for modulating splicing Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
JP2023530645A	Compositions and methods for treating liver damage The present disclosure provides FXR agonists, pharmaceutical compositions thereof, and compounds for preventing, treating, or ameliorating fatty liver disease, e.g., steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatoh...
JP2023530665A	Isotryptamine psychoplastogen and its uses Kind Code: A1 Compounds, compositions, and methods for promoting neural cell growth and/or improving neural cell architecture using the compounds and compositions disclosed herein are described. Also described are methods of using non-ha...
JP7297738B2	Compounds, salts thereof, and methods for the treatment of diseases The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
JP7296641B2	Quinazoline derivatives and uses thereof The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as...
JP7292207B2	Compounds Useful for Treating Gastrointestinal Disorders The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...
JP7291707B2	Aryl- and heteroaryl-substituted indole compounds Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...
JP7291145B2	Substituted Indole Compounds Effective as TLR Inhibitors Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...
JP2023082088A	SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS To provide compounds useful as medicaments in the treatment of conditions and disorders mediated by PRMT5, such as cancer, metabolic disorders, inflammation, autoimmune disease, and hemoglobinopathies.The present invention provides a sub...
JP7289375B2	Inhibitor of SARM1 The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are ...
JP7282743B2	heterocyclic compound Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like.A compound represented by the following formula (I):wherein each symbol is...
JP7282104B2	ABHD12 inhibitor and method for producing and using the same Provided herein are compounds and compositions useful as modulators of ABHD12. Furthermore, the subject compounds and compositions are useful as immunotherapies in treating, for instance, cancer or infectious diseases.
JP2023520917A	TRPC6 inhibitors for treating respiratory conditions The present invention provides a method for treating disorders associated with and/or conditions resulting from vascular hyperpermeability, comprising administering to a patient in need thereof a pharmaceutically effective amount of a TR...
JP7271540B2	Urea derivatives as ASK1 inhibitors The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...
JP2023063270A	PHARMACEUTICAL COMPOSED OF 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE To provide a pharmaceutical composed of a 2-heteroaryl aminoquinazolinone derivative.A pharmaceutical contains a compound represented by formula (1) [where X1 is CR1 or N, X2 is CR2 or N, X3 is CR3 or N, X4 is CR4 or N, Y is optionally s...
JP7264833B2	Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...
JP7264906B2	Alkene compounds as farnesoid X receptor modulators The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the act...
JP7264905B2	Polycyclic compounds as farnesoid X receptor modulators The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of far...
JP2023515780A	heterocyclic PAD4 inhibitor The present disclosure relates generally to substituted heterocyclic compounds of formula (Ia) that are inhibitors of PAD4, to methods of making these compounds, to pharmaceutical compositions containing these compounds, and to the enzym...
JP2023515619A	Compounds and methods for modulating splicing This disclosure features, inter alia, compounds and related compositions that modulate nucleic acid splicing, eg, pre-mRNA splicing, and methods of their use.
JP2023515617A	Pyridazine derivatives for modulating nucleic acid splicing This disclosure features, inter alia, compounds and related compositions that modulate nucleic acid splicing, eg, pre-mRNA splicing, and methods of their use.
JP2023515618A	Pyridazine derivatives for modulating nucleic acid splicing This disclosure features, inter alia, compounds and related compositions that modulate nucleic acid splicing, eg, pre-mRNA splicing, and methods of their use.
JP2023052205A	COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS To provide methods for the treatment of disorders.The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congesti...
JP7254094B2	Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors The present invention relates to substituted imidazolidin-2-one derivatives of formula (I) or pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and uti...
JP2023513419A	Novel Heterocyclic Compounds Useful as Aurora A Selective Inhibitors Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, that can be used to inhibit the activity of Aurora A and to treat cancers mediated by Aurora A.
JP7243959B2	Isoxazole derivative, method for producing same, and use thereof The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a...
JP2023040150A	SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS To provide compounds which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and plasma kallikrein.One embodiment of the present disclosure is a pyrazole compound of the formula (1) illust...
JP7241013B2	Production method of isoflurane Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...
JP2023510778A	nanomaterials Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments, the lipid nanoparticles comprise ionizable lipids of formula (I). Also provided are methods of using such lipid nanoparticle composition...
JP2023509260A	Imidazolylpyrimidinylamine compounds as CDK2 inhibitors The present application provides imidazolylpyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), and pharmaceutical compositions thereof, and methods of using them to treat cancer.
JP7235742B2	Novel sulfonamide carboxamide compound The present invention relates to compounds of formula (I):wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
JP2023509453A	Compounds and compositions for treating CNS disorders The present disclosure provides compounds and pharmaceutical compositions thereof. Also provided are methods of making and using the compounds. The compounds can be used for the treatment, prevention, diagnosis and/or management of vario...
JP2023508930A	TRPML modulator The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using them. [Selection figure] None
JP2023507571A	SOS1 inhibitor The present invention relates to compounds that inhibit Son of Sevenless Homolog 1 (SOS1) activity. In particular, the invention relates to compounds, pharmaceutical compositions, and methods of use, eg, methods of treating cancer using ...
JP2023507509A	Sigma-1 receptor ligands and their therapeutic uses The present invention relates to the medical field. More specifically, the present invention provides compounds that are sigma-1 receptor agonists and cognitive or neurodegenerative disorders such as Alzheimer's disease, Parkinson's dise...
JP7221277B2	Hepatitis B antiviral agent The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function ...
JP7218364B2	Pyrimidine compounds as JAK kinase inhibitors The invention provides a compound of formula (I):or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, me...
JP7214086B2	A novel LXR modulator with a bicyclic core moiety The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRα and/or LXKβ) and act preferably as inverse agonists of LXR.
JP2023502857A	N-(heteroaryl)quinazolin-2-amine derivatives, pharmaceutical compositions and uses thereof as LRRK2 inhibitors The present invention uses the formula (I) [wherein J, R3and R4is as defined herein] and pharmaceutically acceptable salts thereof. Said N-(heteroaryl)quinazolin-2-amine derivatives and pharmaceutically acceptable salts thereof are poten...
JP2023011775A	BIHETEROARYL COMPOUNDS AND USES THEREOF To provide compounds for treatment of diseases (e.g., neurodegenerative diseases).The present invention provides compounds of Formula (I-I) and salts thereof [in the Formula, R1, R2 and R3 are each independently selected from the group c...
JP2023502415A	1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors The present invention relates to compounds of formula (I) and to methods of treatment using said compounds. The compounds of the invention may be used in combination with antibacterial agents to treat bacterial infections. More specifica...

Matches 1,001 - 1,050 out of 2,444	< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 >